| Victoria Belmes, LPN | |
|
2000 Leeward Ln, Newport Beach, CA 92660-3805 | |
| (949) 515-2091 | |
| (949) 515-2091 |
| Full Name | Victoria Belmes |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 2000 Leeward Ln, Newport Beach, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124229174 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | LPN17037 (Nevada) | Primary |
| 164X00000X | Licensed Vocational Nurse | VN193366 (California) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Victoria Belmes, LPN 4040 S Eastern Ave Ste 300, Las Vegas, NV 89119-0854 Ph: (702) 463-0300 | Victoria Belmes, LPN 2000 Leeward Ln, Newport Beach, CA 92660-3805 Ph: (949) 515-2091 |
News Archive
Bioject Medical Technologies Inc., a leading developer of needle-free injection therapy systems, today announced that on December 18, 2009, it completed a Series G Preferred Stock financing with each of Life Sciences Opportunities Fund II, L.P., Life Sciences Opportunities Fund (Institutional) II, L.P. (collectively, the "LOF"), and Edward Flynn for the purchase of an aggregate of 92,448 shares of its Series G Convertible Preferred Stock at a price of $13.00 per share.
A lack of clear-cut, scientific evidence illustrating the benefits of mammography screening in women over 80 has created a trail of controversy leading to a disturbing conclusion about cancer care in America.
A startling presentation at UEG Week 2019, in Barcelona, reveals that the gut microbiome is at high risk for damage each time we use a drug from one or more of 18 commonly used groups. The effects may range from changes in the relative proportions of different beneficial and potentially harmful species to alterations in the cellular metabolism of the bacteria themselves.
A new brain-imaging technique enables people to 'watch' their own brain activity in real time and to control or adjust function in pre-determined brain regions. The study from the Montreal Neurological Institute and Hospital - The Neuro, McGill University and the McGill University Health Centre, published in NeuroImage, is the first to demonstrate that magnetoencephalography can be used as a potential therapeutic tool to control and train specific targeted brain regions.
NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, today reported financial results for the first quarter of 2010.
› Verified 3 days ago